- The disease
- Cancer is a broad category of diseases characterised by uncontrolled cell growth. Early detection is associated with better patient outcomes across many tumour types, yet many cancers lack reliable screening tests for asymptomatic individuals. Liquid biopsy refers to the analysis of tumour-derived material, such as DNA, proteins, or small particles, circulating in the blood as an alternative to tissue sampling. EXO-NET is being developed by Inoviq (ASX: IIQ) as a platform-level diagnostic tool intended to detect multiple cancer types from a blood draw.
- What the asset is trying to do
- EXO-NET is described by Inoviq as a proprietary platform for capturing and analysing exosomes from blood samples. Exosomes are very small particles released by cells, including tumour cells, that carry molecular cargo such as proteins and genetic material reflecting the cell of origin. The intended approach is to isolate tumour-derived exosomes from a patient's blood and analyse their contents for signals indicating the presence of cancer.
- What the trial is measuring, and why it matters
- No clinical trial registration has been identified for EXO-NET in publicly available sources at this time. As a preclinical asset, formal primary and secondary endpoints have not yet been disclosed. For diagnostic devices of this type, registration trials commonly assess sensitivity (the proportion of cancer cases correctly identified) and specificity (the proportion of non-cancer cases correctly excluded), but no such endpoints have been confirmed for EXO-NET.
- Efficacy benchmarks in this setting
- Several liquid biopsy diagnostics have received regulatory authorisation or are in late-stage evaluation as comparators in this space. Guardant Health's Guardant360 CDx is FDA-approved as a companion diagnostic for specific solid tumour indications (per FDA approval records). Grail's Galleri multi-cancer early detection test, which uses methylation-based circulating cell-free DNA analysis, reported a cancer signal detection sensitivity of 51.5% across more than 50 cancer types at a specificity of 99.5% in the PATHFINDER study (per Klein et al, Cancer Cell, 2022). Performance figures vary substantially by cancer type, stage, and assay methodology across published studies. Because EXO-NET has not yet entered clinical trials, no comparative efficacy figures are available, and any early-stage laboratory data would not be statistically comparable to results from fully powered clinical validation studies.
- Commercial context
- No diagnostic product based on the EXO-NET platform has received regulatory approval in any jurisdiction, per publicly available regulatory databases. The multi-cancer liquid biopsy market has seen commercial activity including Illumina's acquisition of Grail for an initially announced consideration of approximately USD 8 billion (per Illumina press release, 2020), though that transaction was subsequently subject to regulatory proceedings in multiple jurisdictions. Inoviq's most recent Quarterly Activities Report is dated April 2026 (ASX release, 27 April 2026); the report's specific content regarding EXO-NET development milestones is . Whether EXO-NET is Inoviq's lead asset or one of multiple pipeline programs is .